Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Management tracks: Sirtex makes interim CEO permanent; plus Magenta, Pyxis, Stoke, Cadent, StemoniX, Enzyvant, Syapse and Stalicla

Sirtex Medical Ltd. (ASX:SRX) named Kevin Smith CEO. He was interim CEO and, before that, the cancer therapy company's EVP, sales & marketing for the Americas. Prior to

Read the full 284 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE